Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioTime Announces China Stem Cell Subsidiary

publication date: Sep 23, 2009

BioTime, Inc. will establish a China subsidiary, called BioTime Asia, to market the company’s stem cell products in China and throughout Asia. The company will also seek to develop stem cell therapies for a number of diseases, including the use of genetically modified stem cells to treat currently incurable forms of cancer. BioTime has engaged the services of Dr. Lu Daopei, a prominent China hematologist, to manage the clinical trials of its therapeutic stem cell products. More details...

Stock Symbol: (OTCBB: BTIM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital